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Abbreviations 
 
A-site Aminoacyl site of the ribosome 
aa-tRNA aminoacyl-tRNA 
CC Conserved cysteine residues 
CTD C-terminal domain 
EF-G Elongation Factor G 
EF-Ts Elongation Factor Ts 
EF-Tu Elongation Factor Tu 
E-site Exit site of the ribosome 
GAP GTPase activating protein 
GAR GTPase center of the ribosome 
GDI Guanine-nucleotide Dissociation Inhibitors 
GDP Guanosine diphosphate 
GEF Guanine-nucleotide Exchange Factor 
Gpp Guanosine pentaphosphate phosphohydrolase 
IC Initiation Complex 
IF1 Initiation Factor 1 
IF2 Initiation Factor 2 
IF3 Initiation Factor 3 
LB Luria-Bertani broth medium 
NTD N-terminal domain of RelA 
P-site Peptidyl site of the ribosome 
PIC Preinitiation Complex 
ppGpp Guanosine 3’, 5’ – bispyrophosphate 
RF1/2 Release Factor 1 or 2 
RF3 Release Factor 3 
RNAP RNA polymerase 
RRF Ribosome Recycling Factor 
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RSHs RelA/SpoT Homologue Proteins  
SAH Small Alarmone Hydrolase 
SAS Small Alarmone Synthetase 
SCV Small Colony Variant 
SRL Sarcin-Ricin Loop 
TC Ternary Complex 
TLC Thin Layer Chromatography  
trGTPases Translational GTPases 
β-Me β-mercaptoethanol  
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Abstract 
The bacterial stringent response is one of the key mechanisms of bacterial adaptation to stress. 
It is mediated by ppGpp alarmone nucleotide that exerts its regulatory role by modulating the 
activity of numerous cellular enzymes, including RNA polymerase, translational GTPases, 
DnaG primase, and, as it was shown in our laboratory recently, of the very protein producing 
ppGpp – the ribosome-dependent stringent factor RelA. Since the stringent response is 
implicated in bacterial virulence, antibiotic tolerance and biofilm formation, identification of 
specific stringent response inhibitors is of great medicinal interest. 
In this thesis I have investigated two types of potential stringent response inhibitors:  
antibiotic thiostrepton and ppGpp-analogues. The primary target of thiostrepton is 
translational GTPases. Inhibition of RelA by thiostrepton is well-documented but was never 
studied in detail, necessitating the current investigation. ppGpp-based RelA inhibitors are 
developed during the last five years, and in their current form have low efficiency and 
bioavailability. 
By comparing thiostrepton effects on RelA and translational GTPase EF-G in the presence of 
wild type and thiostrepton-resistant 70S ribosomes, we conclude that inhibition of RelA by 
thiostrepton is non-specific and is mediated by the precipitation of the antibiotic at high 
concentrations. This suggests that modification of the thiostrepton scaffold is highly unlikely 
to yield an efficient and specific stringent response inhibitor. On the other hand, we 
demonstrated two ppGpp analogues – ppApp and 6-thio-ppGpp – are at least one order of 
magnitude more potent as any of the ppGpp-based RelA inhibitors characterized to date. 
These findings indicate that chemical modifications of the nucleotide base as a promising 
strategy for developing specific and potent stringent response inhibitors. 
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Introduction 
 
1. The stringent response  
Bacterial cells live in continually changing and often hostile environmental conditions. In 
order to survive, they must be able to quickly sense and adapt to changing surroundings. 
Complex regulatory mechanisms have evolved to modulate bacterial physiology when faced 
with nutritional limitation or other stress conditions [1]. To conserve energy under nutrient 
starvation bacteria employ a mechanism named ‘the stringent response’ – a pleiotropic 
physiological process leading to succession of growth and division and simultaneous 
upregulation survival responses, such as amino acid synthesis [1, 2]. These changes are 
accomplished by reallocation of cellular resources so that synthesis of DNA, stable RNAs, 
ribosomal proteins and membrane components is repressed, whereas production of proteins 
involved in the stress resistance, glycolysis and amino acid synthesis dramatically increases 
[3]. The stringent response is mediated by an alarmone molecule named guanosine 3’, 5’ - 
bispyrophosphate or ppGpp, which is, amongst other things, coordinating this reallocation of 
gene expression at the transcriptional level by binding to RNA polymerase (RNAP) and 
regulating certain promoters [4].  
1.1 RSH proteins 
The intracellular levels of the ppGpp are controlled by the RelA/SpoT Homologue proteins 
(RSHs), with the name coming from two RSH representatives in Escherichia coli: RelA and 
SpoT. Under the conditions of amino acid deprivation accumulation of deacylated tRNA in 
the ribosomal A-site is sensed by stringent factor RelA. Activated by the tRNA RelA 
catalyzes production of ppGpp (or pppGpp) using ATP and GDP (or GTP) as substrates 
(Figure 1). ppGpp acts as a primary regulatory nucleotide, as pppGpp after its synthesis is 
rapidly degraded to ppGpp by guanosine pentaphosphate phosphohydrolase (gpp) [5]. 
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Figure 1. Synthesis of ppGpp from GDP and ATP 
RelA’s catalytic activity resides in the SYNTH domain (Figure 2). The other E. coli RSH is 
SpoT is a bi-functional protein with strong ppGpp hydrolysis activity in HD domain and weak 
synthetic activity in the SYNTH domain [6]. Synthetic activity of the SpoT protein is induced 
by many types of nutrient stress other than amino acid starvation, e.g. limitation of phosphate, 
carbon, fatty acid and iron [4]. SpoT hydrolase activity is essential to bacterial cells, as high 
concentrations of ppGpp result in cell cycle arrest by inhibiting the DNA replication [7]. HD 
domain is also present in RelA, but in an inactive form [8]. CTD region of RSH proteins has a 
regulatory function upon the NTD region as it contacts the HD and SYNTH domains [9]. 
In the case of many gram-positive model organisms (like Mycobacteriym tuberculosis and 
Bacillus subtilis) a single enzyme named Rel is responsible for both synthesis and degradation 
of the alarmone molecule [10]. Like SpoT, Rel is bifunctional protein with active SYNTH and 
HD domains.  In general, these three enzymes - Rel, RelA and SpoT - are referred to as 
“long” RSH-s and have a six-domain structure, comprising of HD, SYNTH, TGS, helical, 
conserved cysteine residues (CC) and ACT domains [8]. However, in addition to “long” 
RSH-s there are also shorter and specialized RSH-s that contain either the SYNTH or the HD 
domain. These are Small Armone Synthetases (SASs) and Small Alarmone Hydrolyses 
(SAHs) (Figure 2). 
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Figure 2. Structure of RSH proteins as per [8]. First line is the structure of “long” RSHs, which 
comprise of six domains: HD, SYNTH, TGS, helical, conserved cysteine residues (CC) and ACT 
domains. Rsh4 is a “long” RSH representative in plants – cTP stands for chloroplast transit peptide 
and Efh for EF hand domain. SAH and SAS are “short” RSHs comprising of only HD or SYNTH 
domains respectively. 
 
1.2 Molecular mechanisms of ppGpp-mediated regulation 
Nucleotides ppGpp and pppGpp were first discovered by Cashel and Gallant [11] as “magic 
spots” on a thin layer chromatogram  while analyzing changes in intracellular nucleotide 
pools in response to the nutritional stress. They have postulated that accumulation of these 
compounds led to suppression of RNA synthesis during the stringent response [12]. Since 
then, extensive genetic and molecular investigations of E. coli have established that in this 
bacteria ppGpp exerts its global regulatory activity mainly by acting on RNA polymerase 
(RNAP) in two ways: directly, by regulating the RNA polymerase and indirectly, by 
regulating concentrations of the RNAP sigma factors [4]. 
Direct effects of ppGpp on RNAP are further potentiated by its cooperation with a protein that 
binds to the polymerase – DnaK supressor DksA. DnaK is a negative regulator of the heat 
shock response and E. coli dksA gene was first discovered as a dosage dependent suppressor 
of growth and filamentation phenotypes of dnaK deletion mutant strains [13]. Since then 
DksA have been implicated in a variety of cellular processes including cell division, the 
stringent response, expression of virulence factors etc. Its role in manifestation of the 
stringent response has been connected to its ability to bind to the RNAP secondary channel 
thereby stabilizing ppGpp binding to the RNAP [14]. DksA augments ppGpp effects on 
initiation and e.g DksA and ppGpp together directly and specifically inhibit the transcription 
from rRNA promoters, ribosomal protein and tRNA promoters. A strong correlation between 
the short lifetime of the competitor-resistant promoter complex and negative regulation by 
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ppGpp and DksA has been found. This leads to suggestion that they inhibit transcription 
initiation only from those promoters that make short-lived complexes with the RNAP and fail 
to inhibit from promoters with long-lived complexes [15, 16].    
Indirect effects of ppGpp on the RNA polymerase are mediated by so-called called sigma-
factor competition [17]. Sigma factors (σ) are dissociable subunits of RNA polymerase, that 
are responsible for recognition of promoter sequences during initiation of transcription [18]. 
During the logarithmic growth vegetative sigma factor σ70 directs transcription initiation from 
operons that are essential for synthesis of proteins, lipids and DNA. During the stringent 
response high concentrations of ppGpp interfere with RNAP binding to the strong σ70-
dependent promoters, such as the promoters of ribosomal RNA, ribosomal protein and tRNA 
genes [19]. This leads to inhibition of the rRNA and tRNA synthesis, and at the same time 
more core RNAP is available to bind to the alternative σ factors which direct RNAP to 
transcribe genes involved in adaptive responses [4, 18].  
In addition to directing RNAP promoter selection ppGpp exerts broad influence on bacterial 
physiology [4]. For example, ppGpp controls cellular growth rate by regulating ribosomal 
number, accumulation of ppGpp leads to DNA replication arrest [20], also it inhibits 
translation by binding to translational GTPases Initiation Factor 2 (IF2) and Elongation Factor 
G (EF-G) [21]. Unlike in the case of E. coli RNAP, in B. subtilis ppGpp does bind to the 
RNAP and the stringent response exerts its regulatory effects via reduction of the GTP levels 
during starvation [22]. Recently, the stringent response has been found to be linked to 
bacterial acid stress, via ppGpp-mediated regulation of lysine carboxylase – an enzyme 
crucial for survival in the acidic environment [23]. 
1.3 ppGpp-mediated regulation of bacterial virulence and antibiotic resistance 
The stringent response has been implicated in bacterial virulence, antibiotic resistance and 
microbial persistence [24]. There is a growing evidence that ppGpp plays a key role for 
pathogens to successfully adapt to different microenvironments encountered during infection 
within the host organism [24] and for expression of virulence genes [25]. In several 
pathogenic bacteria (Mycobacterium tuberculosis, Listeria monocytogenes and many others) 
mutations in rel gene lead to diminished ppGpp accumulation and loss of long-term 
persistence ability during infection, also they show avirulent phenotype [26]. ppGpp is also 
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shown to be essential for pathogens to survive and replicate in the phagocytes. The stringent 
response is activated after uptake of Staphylococcus aureus in neutrophils and ppGpp activity 
is crucial for intracellular expression of genes, coding for factors mediating bacterial survival 
and escape after phagocytosis [27].  
A growing body of evidence indicates that the stringent response contributes towards the 
antibiotic resistance and formation of non-dividing persister cells [28]. In the investigation of 
molecular determinants of antibiotic resistance and formation of small colony variant (SCV) 
phenotype in S. aureus it has been found that minor mutation in RelA coding gene is the 
cause of antibacterial tolerance and formation of persister cells. Mutation detected in relA 
partially impairs hydrolase function of the enzyme, leading to accumulation of ppGpp and 
result in reduced growth rate of pathogen, attenuated virulence, reduced antibiotic 
susceptibility – the key features of persistent infection [29].  In a different study it has also 
been found that attenuation of the ppGpp synthase RelA reduces the antibiotic tolerance, 
which also confirms importance of ppGpp in resistance mechanisms [30].  
 
2. Role of Translational GTPases in Ribosomal cycle 
GTPases is a large protein family with members involved in a variety of cellular processes 
including protein biosynthesis, various transport processes, as well as cell growth and 
differentiation [31]. The common feature of all GTPases is their ability to bind GTP 
nucleotide and hydrolyze it to GDP, releasing inorganic phosphate.  
They are as molecular switches that cycle between inactive GDP-bound and active GTP-
bound states, so called OFF (or D) and ON (or T) states (Figure 3). The GTPase cycle is 
regulated by a variety of modulators. GTP hydrolysis and consequent transition from ON to 
the OFF state is strongly activated by GTPase Activating Proteins (GAPs) [32]. Re-activation 
of the protein requires dissociation of GDP from the protein and its replacement with GTP. 
This is often a very slow process, which is accelerated by Guanine-nucleotide Exchange 
Factors (GEFs). Spontaneous exchange of GDP for GTP is inhibited by Guanine-nucleotide 
Dissociation Inhibitors (GDIs), which stabilize both GTPase:GTP and GTPase:GDP 
complexes [33]. 
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Figure 3. Functional cycle of translational GTPases. “T” and “D” represent the GTP and GDP 
bound forms of the GTPases, respectively. GAP stands for GTPase Activating Protein and GEF for 
Guanine-nucleotide Exchange Factor. Wavy arrows represent the stabilization effect of the GDI 
(Guanine-nucleotide Dissociation Inhibitor). Apo is nucleotide-free state of the GTPase.   
GTPases that are involved in protein biosynthesis are referred to as translational GTPases 
(trGTPases). Their GTPase activity is induced by several elements of the large ribosomal 
subunit (see below) [34]. In bacteria the “classical” set of trGTPases comprises Initiation 
Factor 2 (IF2), Elongation Factor Tu (EF-Tu), Elongation Factor G (EF-G) and Release 
Factor 3 (RF3), which play crucial role in all stages of translation: initiation, elongation, 
termination and ribosome recycling (Figure 4) [35, 36]. 
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Figure 4. Bacterial translational cycle [37]. The four stages the ribosomal cycle are initiation, 
elongation, termination and recycling. During the initiation ribosomal subunits, mRNA and the 
initiator tRNA are brought together with the help of initiation factors IF1, IF2, IF3. During the 
elongation aa-tRNAs in complex with EF-Tu and GTP are delivered one by one to the ribosomal A-
site and amino acids are added to the growing polypeptide chain. After codon-anticodon cognition EF-
Tu hydrolyzes GTP and dissociates from the complex. This is followed by EF-G-catalyzed 
translocation, and post-translocational ribosome formation with peptidyl-tRNA in the P-site, 
deacylated tRNA in the E-site and empty A-site. Termination occurs when stop-codon enters the A-
site of the ribosome and the completed polypeptide is released with the help of RF1 or RF2. RRF and 
EF-G:GTP complex catalyze the splitting of ribosome subunits in the process known as ribosome 
recycling. The figure is adapted from [37]. 
 
2.1 Initiation 
Translation initiation is the starting phase of the protein biosynthesis which prepares the 
ribosome to enter the elongation cycle [38]. Initiation begins with positioning of the 30S 
ribosomal subunit and initiator tRNA at the start codon of the mRNA forming the Pre-
Initiation Complex (PIC). Afterwards, joining of the 50S subunit and 30S PIC takes place to 
form the 70S Initiation Complex (70S IC).  
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In bacteria, this process involves three Initiation Factors – IF1, IF2 and IF3. Initiation factors 
IF1 and IF3 guide the assembly of PIC. IF1 binds to the aminoacyl site (A-site) of the 30S 
ribosomal subunit and guides the initiator tRNA to the peptidyl site (P-site) of the ribosome 
[39]. IF3 binds to the 30S subunit and prevents its premature association with the 50S subunit, 
as well as participates in selection of initiator tRNA [40]. IF2 recognizes the formyl group of 
the initiator tRNA and stabilizes its interaction with the 30S subunit [41]. In the next step IF2 
accelerates the joining of 30S PIC and 50S ribosomal subunits. After 70S ribosome has been 
formed, IF2 hydrolyzes GTP, ribosome becomes capable of elongation and IF2 dissociates 
from the ribosome [42]. 
2.2 Elongation 
During translation elongation amino acids are added one by one to the growing polypeptide 
chain in accordance with the information encoded in mRNA. In bacteria, this process is 
catalyzed by two trGTPases: EF-Tu and EF-G.  
At the beginning of the cycle tRNA with nascent peptide chain linked to it is in the peptidyl-
tRNA binding site of the ribosome (P-site). The incoming aminoacyl-tRNA (aa-tRNA) is 
docked to the empty aminoacyl-tRNA site (A-site) of the ribosome as a ternary complex (TC) 
with EF-Tu and GTP [43]. Base pairing between the codon on mRNA and the anticodon on 
tRNA leads to stabilization of the tRNA in the A-site and triggers the GTP hydrolysis by EF-
Tu [44].  Hydrolysis of GTP dramatically decreases the affinity of EF-Tu for aa-tRNA and 
leads to subsequent release of the GTPase from the ribosome in GDP-bound form. Exchange 
of EF-Tu bound GDP with GTP is catalyzed EF-Tu’s GEF – EF-Ts [45]. GTP hydrolysis by 
EF-Tu separates two steps in the correct codon-anticodon selection: initial selection and 
subsequent proofreading [46]. Initial selection is reversible process of ternary complex 
binding to the ribosome, where the non-cognate ternary complex usually dissociates from the 
ribosome and cognate one promotes GTP hydrolysis (irreversible process). Following the 
GTP hydrolysis, tRNA is either accommodated into the peptidyl transferase center or rejected 
- this is the second proofreading step [47]. After the tRNA accommodation, peptide chain is 
transferred from P-site tRNA to A-site tRNA. Following the peptidyl transfer, the ribosome 
has a deacylated tRNA in the P-site and peptidyl tRNA in the A-site [44], and now serves as a 
substrate for the second GTPase involved in elongation: EF-G.  
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To prepare the ribosome for the accommodation of next aa-tRNA, the assembly of tRNAs and 
mRNA must move in respect to the ribosome by one codon in a process known as 
translocation. Translocation completes the round of elongation and leaves ribosome with 
peptidyl-tRNA in P-site and deaminoacylated tRNA in the E-site. Hydrolysis of GTP by EF-
G is required for catalyzing this movement [48].  
2.3 Termination 
Translation termination occurs when one of the three stop codons (UAG, UGA or UAA) 
enters the A-site of the ribosome and is specifically recognized by a class 1 Release Factor (in 
bacteria RF1 or RF2). Both factors recognize UAA codon, whereas UAG is recognized 
specifically by RF1 and UGA by RF2. Upon stop-codon recognition, class 1 RFs facilitate the 
hydrolysis of the ester bond that links the nascent polypeptide chain to P-site tRNA, and 
thereby induce the release of the completed peptide [49]. Subsequent dissociation of class 1 
RF-s from the ribosome is driven by another ribosomal GTPase – RF3 [50]. By stimulating 
the release of RF1/RF2 from the ribosome RF3 also accelerates the transition from 
termination step to ribosomal recycling, while for the latter process required Ribosome 
Recycling Factor (RRF) and class 1 RFs have the overlapping binding site on the ribosome 
[51].  
2.4 Ribosomal recycling 
After release of the peptide chain, the ribosome is left in complex with mRNA and a 
deacylated tRNA in the P-site. This complex needs to be disassembled in order to prepare the 
ribosome for a new round of protein synthesis. Three proteins are responsible for this process: 
RRF, EF-G and IF3 [52]. RRF and EF-G serve to disassociate the ribosomal subunits in the 
reaction requiring GTP hydrolysis [53, 54]. This leaves 30S subunit with mRNA still bound 
to it containing as well the deacylated tRNA. IF3 then displaces the mRNA and tRNA and 
allows the 30S subunit to recycle. IF3 also prevents the ribosome from premature re-
association [54].  
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3. Key structural elements of the ribosome 
3.1 Regulation of translational GTPase 
The activity of trGTPases is regulated by the ribosome. Structural studies showed that G-
domains of all bacterial trGTPases interact with the ribosome at a common site near the 
sarcin-ricin loop (SRL) [48, 55, 56]. This conserved region of the large ribosomal subunit 
includes part of domain II of 23S RNA (the binding site of antibiotic thiostrepton), part of 
domain IV (SRL), and proteins L11 and L7/L12, and is responsible for activating trGTPases 
[36, 44]. 
The sarcin-ricin loop (SRL), a part of the ribosomal RNA, that is targeted by sarcin and ricin 
toxins, directly interacts with trGTPases [56] and is suggested to play a crucial role in 
activating the GTP hydrolysis [57]. However recent studies have shown that SRL acts solely 
as an anchoring point for GTPase binding and is not involved in the GTPase activation [58]. 
In vitro analysis demonstrated that SRL:EF-G or SRL:IF2 complex formation is inhibited by 
GDP, while being insensitive to GTP [59]. This leads to suggestion that SRL could play a role 
in discrimination between GTP- and GDP-bound forms of EF-G or IF2. It also provides a 
mechanism for selective destabilization of GDP-bound forms of trGTPases on the ribosome 
after GTP hydrolysis [59]. 
A prerequisite for binding of trGTPases to the ribosome is conformational change of N-
terminal domain of L11 protein from inactive trans to the active cis configuration, which 
enables L11 NTD to connect to L12 CTD. This isomerization was suggested to be catalyzed 
by EF-G (or other trGTPases) [60]. N-terminal domain of L11 protein also forms along with 
the helixes 43 and 44 of 23S ribosomal RNA (rRNA) the target site for thiazole-family 
antibiotics such as thiostrepton and micrococcin. Thiostrepton is known to inhibit the EF-G 
dependent translocation, by causing the L11 NTD to become more rigid [61, 62].  
Ribosomal protein L7/L12 promotes recruitment of trGTPases to the ribosome and stimulates 
the GTP hydrolysis by the ribosome-bound translation factors through stabilization of their 
active GTPase conformation. In E. coli there are four copies of L7/L12 proteins bound to the 
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ribosome via N-terminal domain. C-terminal domains of the protein are highly mobile and are 
crucial for the functional interactions with translation factors [63].  
3.2 Regulation of RelA 
Besides the assumable functions of binding and activation of trGTPases, ribosomal protein 
L11 is also implicated in the stringent response by regulating the activity of RelA [64]. 
Ribosomes that are lacking L11 are deficient in activating the ppGpp synthesis, at the same 
time being capable of binding RelA [65]. 
L11 protein consists of dynamic N-terminal domain connected to an RNA-binding C-terminal 
domain. N-terminal domain has been shown to be involved in the interaction with EF-G, RF1, 
and antibiotics thiostrepton and micrococcin [64]. NTD has a highly conserved proline-rich 
helix that lies on the surface of L11 facing away from the ribosome. Mutations in this region 
or its absence lead to resistance to above mentioned antibiotics as well as relaxation of the 
stringent response phenotype. Mutational analysis showed that a point mutation of the proline 
22 of L11 protein renders it unable to stimulate ppGpp synthetic activity of RelA (see below) 
[66].  
 
4. Inhibitors of the stringent response 
The stringent response is an important mechanism for pathogens to express their virulence 
genes and to survive in the host organisms (see section 1.3). However, rsh genes, encoding 
the stringent factor are widespread only in Bacteria and plants, but have not yet been found in 
animals. Therefore the stringent response is considered possible therapeutic target and 
inhibition of the stringent response is of great medical interest [26]. Several antibiotics 
targeting translation and ppGpp analogue molecules are acting as inhibitors of the stringent 
response.  
4.1 Antibiotics 
The most well-characterized examples of antibiotics inhibiting the stringent response are 
thiostrepton and tetracycline. They have been shown to interfere with the ribosome-dependent 
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ppGpp synthesis [67] and the mutations in the L11 protein, which confer resistance to 
thiostrepton lead also to inhibition of ppGpp synthesis [68].  
Tetracycline and thiostrepton are both A-site specific antibiotics inhibiting the protein 
synthesis. Tetracycline exerts its activity by blocking tRNA binding to the A-site of the 
ribosome [69]. As the unaminoacylated tRNA in the A-site of the ribosome is a prerequisite 
for activation of the stringent response, and tetracycline blocks binding of any tRNA, 
tetracycline has been shown to inhibit the ppGpp synthesis [65].  
Thiostrepton on the other hand perturbs the function of the elongation factors by binding to 
the GTPase center of the ribosome (GAR). Two sites of the GAR are found to be essential for 
thiostrepton binding: region around residue A1067 of the 23S rRNA [70], which is also the 
binding site for L11, and proline rich area of L11 protein.  There are several lines of evidence 
that thiostrepton binds strongly and primarily to rRNA in the 1067 region. First, Streptomyces 
azureus, the producer of thiostrepton, possesses the methylase specific for 2’O of A1067, 
conferring total and selective resistance to the thiostrepton [71]; second, ribosomes containing 
adenine to uracil substitution at residue 1067 are as well thiostrepton resistant and show 
weakened thiostrepton binding [72]. Mutations in conserved proline residue of L11 protein on 
the other hand did not affect the binding affinity of protein to the rRNA nor the binding of 
thiostrepton. But mutation does result on thiostrepton-resistant phenotype [73]. It has been 
proposed that thiostrepton by binding in the close vicinity of L11 [74], interferes with 
conformational transitions in L11, which are important for its functioning [75]. Therefore, it 
was suggested that thiostrepton inhibits ppGpp synthesis by blocking the function of L11. 
Unlike in the case of translational GTPases, effects of thiostrepton on the stringent response 
where never investigated using thiostrepton-resistant ribosomes, therefore specificity of the 
inhibition was never established. All of the reported experiments were performed at fixed 
concentration of thiostrepton (commonly 10 µM), prompting more quantitative analysis. 
4.2 ppGpp analogues 
As traditional antibiotics target essential cellular components, which makes them effective 
mostly during bacterial growth, a series of novel ppGpp analogue antibacterial compounds 
were synthesized. These compounds impede bacterial long term survival pathways as they 
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inhibit RelA activity, which is responsible for bacterial alternative survival strategies. For the 
mechanism of inhibition has been suggested that ppGpp analogues bind to the catalytic site of 
the Rel proteins, competing with the GTP/GDP for the same binding site [76, 77]. 
The only of these compounds that was shown to have effects not only in vitro, but also when 
added to live cells is Relacin [78]. Relacin has been shown to inhibit RelA and reduce ppGpp 
production as well as affect entry into stationary phase in Gram positive bacteria and disrupt 
formation of multicellular biofilms, making it a promising lead compound for developing a 
specific inhibitor of the stringent response interfering with bacterial long-term survival 
mechanisms [78]. 
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Aims of the project 
 
1. Validation of the specificity of thiostrepton-mediated inhibition of the stringent 
response.  
2. Characterization of the stringent response inhibition by ppGpp-based inhibitors.  
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Materials and Methods 
1. Preparation of E. coli ribosomes 
1.1 Wild type ribosomes 
E. coli strain MRE600 was grown at 37°C in a liquid Luria-Bertani (LB) medium. Cells were 
allowed to grow until OD600=1.1. The bacteria were then collected by low speed 
centrifugation (4500 g, 20 minutes) and resuspended in cell opening buffer (20 mM Tris-HCl 
pH 7.5, 100 mM NH4Cl, 15 mM Mg-acetate, 0.5 mM EDTA, 6 mM β-mercaptoethanol, 20 
U/ml DNase I and 0.1 mM PMSF). The suspension was lysed using EmulsiFlex-C3 High 
Pressure Homogenizer. The lysate was diluted with one volume of 1x overlay buffer (20 mM 
Tris-HCl pH 7.5, 60 mM NH4Cl, 15 mM Mg-acetate, 2.5 mM EDTA and 3 mM β-
merkaptoethanol (β-Me)). The cell debris was pelleted by centrifuging the lysate for 50 min at 
18 000 rpm in SS 34 Sorvall rotor. Supernatant was loaded on sucrose cushion buffer (20 mM 
Tris-HCl pH 9.0, 500 mM NH4Cl, 15 mM Mg-acetate, 0,5 mM EDTA, 3 mM β-
merkaptoethanol, 1.1 M sucrose) and centrifuged through cushion in Ti 50.2 rotor 17 – 19h at 
28000 – 30000 rpm at 4°C. Pellet was dissolved in washing buffer (20 mM Tris-HCl pH 7.5, 
500 mM NH4Cl, 15 mM MgOAc, 0.5 mM EDTA, 7 mM β-Me) and washed again through 
sucrose cushion buffer in Ti 50 rotor at ω2t = 3,85*1011 rad2s, 4 °C. The precipitate was 
redissolved in 30 mL of 1x overlay buffer and loaded to a 15-30% sucrose gradient in overlay 
buffer. 70S ribosomes and free subunits were then fractionated by centrifugation in zonal Ti-
14 rotor at ω2t=4.67x1011 rad2/s at 4°C. Fractions containing 70S were collected and pelleted 
by centrifugation at ω2t=1.12x1012 rad2/s at 4°C in Ti-45 rotor. The pelleted 70S subunits 
were redissolved in 1x Polymix buffer (25 mM Hepes pH 7.5, 15 mM MgCl2, 0.5 mM CaCl, 
95 mM KCl, 5 mM NH4Cl, 8 mM putrescine, 1 mM spermidine, 5 mM K3PO4 pH 7.3 and 1 
mM 1,4-dithioerytreithol), shock-frozen in liquid nitrogen and stored at -80°C. Concentration 
was estimated by measuring OD at the wavelength 260 nm considering that 1 OD260 unit 
equals 24 pmols.  
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1.2 Mutant ribosomes: A1067U and ΔL11 
For preparation of A1067U mutant ribosomes E. coli strain MC315 containing pKK3535 
(ampicillin resistant) plasmid was used. This strain was a gift from Dr. Aivar Liiv [79]. Strain 
for ΔL11 ribosomes was provided by Dr. Scott Blanchard [80]. The process of mutant 
ribosomes’ preparation was the same as for the wild type ribosomes, except the cells were 
harvested at OD600 0.8. 
 
2. Preparation of recombinant proteins, nucleotides 
2.1 E. coli 6His RelA 
E. coli 6His RelA protein was purified from BL21 (DE3) cells transformed with pET24b 
plasmid encoding C-terminally 6His-tagged RelA [81]. Cells were grown in liquid LB 
medium containing 50 µg/ml kanamycin. Protein expression was induced with 0.5 mM 
isopropyl thio-β-Dgalactosidase (IPTG) at OD600 = 0.5 and grown additional 3 h at 37 °C. 
Cells were harvested by centrifugation 15 minutes at 3000 rpm and diluted in cell opening 
buffer (25 mM Tris pH 7.5, 1 M Na Cl, 2 mM MgCl2, 1 mM β-Me, 5 mM Imidazole) with 
addition of 1 µg/ ml DNase-1 and 1 mM PMSF.  Cells were lysed by Avestin EmulsiFlex-C3 
High Pressure Homogenizer after which cell debris was removed by centrifugation for 20 
minutes at 15 000 rpm. Supernatant was then diluted 3 times by Opening buffer without salt 
(25 mM Tris pH 7.5, 2 mM MgCl2, 1 mM bME, 5 mM imidazole) and loaded on the 1 ml 
His-trap Ni2+ column (GE Healthcare) equilibrated with Washing buffer: 25 mM Tris (pH 7.5-
8), 350 mM NaCl, 2 mM MgCl2, 5 mM imidazole, 1 mM bME. Finally the protein was 
eluted, by washing the column with Elution buffer (25 mM Tris pH 7.5, 350 mM NaCl, 2 mM 
MgCl2, 300 mM imidazole, 1mM bMe). Collected fractions were ran on 10% SDS-PAGE and 
then the fractions showing the pure protein were concentrated against RelA Storage buffer 
(0.7M KCl, 25 mM Hepes, 2mM DTT, 5mM MgCl2, 10% Glycerol) using Amicon Ultra 
Centrifugal Filters. Protein concentration was measured by Bradford protein assay. Protein 
was aliquoted, shock-frozen in liquid nitrogen and stored at -80 °C. 
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2.2 E. coli 6His EF-G  
E. coli 6His EF-G protein was purified from BL21 (DE3) cells transformed with pRSET 
plasmid encoding N-terminally 6His-tagged EF-G [82]. Cells were grown in a liquid LB 
medium with 50 µg/ml Kanamycin. Protein expression was induced with 0.5 mM IPTG at 
OD600 = 0.6 and cells were grown additional 2 h at 30 °C. Cells were harvested by 
centrifugation at 3500 rpm at 4 °C. The cell pellet was dissolved in lysis buffer (50 mM Tris-
HCl pH 7.5, 10 mM MgCl2, 200 mM NaCl), 1 µg/ ml DNase-1 and 1 mM PMSF were added 
and cells were lysed with Avestin EmulsiFlex-C3 High Pressure Homogenizer. Cell debris 
was removed by centrifugation at 15 000 rpm for 20 minutes 4 °C and supernatant was loaded 
to 1 ml His-trap Ni2+ column (GE Healthcare) equilibrated with loading buffer (50 mMTris-
Hcl pH 7.5, 200 mM NaCl). Finally the protein was eluted from the column by elution buffer 
(50 mM Tris-HCl pH 7.5, 200 mM NaCl, 300 mM Imidazole). For purity check the protein 
was ran on 12% SDS-PAGE and then concentrated in 1x Polymix through Amicon Ultra 
Centrifugal Filters (Merck KGaA) by centrifuging at 4000 rpm. Protein concentration was 
estimated by Bradford protein assay. Finally the concentrated protein was aliquoted, shock-
frozen in liquid nitrogen and stored at -80 °C. 
2.3 ppGpp 
ppGpp was prepared using the RelSeq enzyme from Streptococcus equisimillis essentially as 
described by Mechold and colleagues [9], with minor modifications. 
For ppGpp preparation, a 500 µl reaction mixture containing 30 mM Tris pH 8.0, 100 mM 
NaCl, 10 mM MgCl2, 10 mM ATP, and 6 mM GDP is initiated by adding 50 µl of purified 
RelSeq [9] (final concentration of 100 µM) and, incubated for at least 30 minutes at 37°C. 
Reaction was stopped with the equal volume of phenol and centrifuged at 16000 g for 20 
minutes. After centrifugation the aqueous phase was loaded on the MonoQ 5/50 GL (GE 
Healthcare Bio-Sciences AB) column equilibrated with Buffer A (0.5 mM LiCl, 0.5 mM 
EDTA, 2.5 mM TrisCl pH 7.5). For ppGpp purification, nucleotides were eluted with Buffer 
B (2 M LiCl, 0.5 mM EDTA, 2.5 mM TrisCl pH 7.5). Nucleotides were monitored in 
fractions by following the UV absorption at 253 nm and verified by TLC mobilities relative to 
GTP. Fractions containing ppGpp were collected and precipitated by adjusting LiCl to 1 M, 
then adding 3 volumes of 95% EtOH. This was kept 1 h at -80 °C (or -20 °C overnight) and 
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then centrifuged 16000g for 20 minutes. The pellet was dried using MAXI dry plus Heto 
Vacuum Centrifuge. After, the pellet was dissolved in H2O. Final concentration was 
determined spectrophotometrically at 254 nm using molar extinction coefficient of 13600.  
2.4 thio-ppGpp 
For 6-thio-ppGpp preparation was used the same procedure as for ppGpp with the exception 
of used substrate, 6-thio-GDP (Jena Biosciences) instead of GDP. 
2.5 ATP 
ATP (Amersham Biosciences) was dissolved in water until concentration of 20 mM and pH 
was adjusted with NaOH to 7.5. 
 
3. In vitro assays 
All biochemical reactions were carried out in high-fidelity 1x Polymix buffer for in vitro 
translation mimicking in vivo conditions [83]: 25 mM Hepes pH 7.5, 15 mM MgCl2, 0.5 mM 
CaCl, 95 mM KCl, 5 mM NH4Cl, 8 mM putrescine, 1 mM spermidine, 5 mM K3PO4 pH 7.3 
and 1 mM 1,4-dithioerytreithol. High concentrations of magnesium ions where used for 
efficient non-enzymatic tRNA binding to the ribosome. 
3.1 The stringent response system 
The RelA mediated ppGpp production in the presence of different RelA inhibitors was 
investigated by monitoring the ppGpp production from GDP and ATP, using the 3H-labeled 
GDP. Process of reaction was quantified as 3H-GDP to 3H-ppGpp conversion, ranging from 
0 (no 3H-ppGpp is produced) to 1 (all the 3H-GDP is converted to 3H-ppGpp). 
The stringent response system experiments were performed with 30-100 nM RelA, 0.5 µM 
70S (wild type or ΔL11), 0.3 mM 3H-labeled GDP (purchased from American  Radiolabelled 
Chemicals), 1 mM ATP, 100 µM ppGpp and titration by different concentrations of RelA 
inhibitors.  
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RelA inhibitors tested: 
1) Antibiotic thiostrepton (Tocris Bioscience) 
2) ppGpp analogue molecules: thio-ppGpp, ppApp, Relacin (the latter two compounds 
were synthesized by Dominik Rejman at the Institute of Organic Chemistry and 
Biochemistry, Academy of Sciences of the Czech Republic) 
Reactions were performed at 37 °C and reaction mixes were preincubated for 2 minutes 
before the reaction was started by addition of ATP. After activation, to monitor ppGpp 
production (from ATP and GDP) in time, reactions were stopped at 0, 5, 10 and 15 minute 
timepoints by Kill Mix solution (71% Formic Acid, 4 mM GDP, 4 mM GTP). The 
concentration of formic acid after addition of Kill mix to the reaction is 30 %.  In the reaction 
with ΔL11 ribosomes due to considerably lower activity of RelA in this system timepoints 
were taken at 0, 10, 20 and 40 minutes. Stopped reaction mixes were loaded on POLYGRAM 
CEL 300 PEI/UV254 Pre-coated Thin Layer Chromatography (TLC)-sheets (MECHEREY-
NAGEL). After the samples have been eluted, separated nucleotides were visualized by 
UV254-light and GDP and ppGpp spots were cut out from the TLC sheets. Cut out peaces 
were subjected to ScintiSafe 3 Liquid Scintillation Cocktail (Fischer Scientific) and with the 
usage of Perkin Elmer Liquid Scintillation Analyzer the production of 3H-ppGpp from 3H-
GDP was counted. 
3.2 EF-G GTPase reaction 
GTP hydrolysis by EF-G was monitored by using 3H-labeled GTP and quantified as 
conversion of 3H-labeled GTP to 3H-labeled GDP.  
EF-G GTPase reactions were performed with 0.1 µM EF-G, 0.5 µM 70S, 0.5 mM 3H-labeled 
GTP (AMERSHAM) diluted by cold GDP. This reaction mix was titrated by different 
concentrations of GTPase inhibitor compounds (the same inhibitors as in stringent response 
system). Reactions with thiostrepton were performed in the presence of 0.1 µM Pluronic F-
127 (Sigma) for dissolving the water-insoluble thiostrepton. 
 
 25 
Following procedures were similar to the stringent response system reaction: 
1. Reaction preincubation for 2 minutes at 37 °C 
2. Activation of the reaction by 3H-GTP dilution 
3. Stopping reaction by taking 0, 5, 10 and 15 minute timepoints 
4. Loading the samples on TLC and eluting 
5. Cutting out GDP and GTP spots and subjecting them to scintillation cocktail 
6. Counting the 3H-GDP production from 3H-GTP by Liquid Scintillation Analyzer  
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Results 
1. Effects of thiostrepton 
1.1 Inhibition of EF-G GTPase  
As a specificity control of thiostrepton-mediated inhibition of RelA we decided to use a well-
studied inhibition of in vitro EF-G GTPase, taking advantage of well-characterized ribosomal 
mutants resistant to thiostrepton [72, 84]. Since thiostrepton has a tendency for precipitation, 
which can lead to artifacts [85], we have performed experiments in the presence and absence 
of 0.1% of Pluronic F-127 – a nonionic surfactant polyol used for solubilizing hydrophobic 
compounds [86].  
As a first control we showed that at 0.1% Pluronic F-127 does not affect EF-G GTPase 
activity, both in the presence and absence of E. coli 70S ribosomes (Figure 5). Next we 
performed a titration of thiostrepton following EF-G GTPase in the presence of thiostrepon-
sensitive (wild type) as well as thiostrepton-resistant (A1067U rRNA mutant and a mutant 
missing ribosomal protein L11, ΔL11) E. coli ribosomes (Figure 6). 
 
Figure 5. 0.1% Pluronic F-127 does not affect EF-G GTPase activity. The reaction mixture 
contained 0.5 µM 70S ribosomes (wild type or A1067U), 0.1 µM EF-G, 300 µM 3H-GTP, Polymix, 
0.1 % Pluronic F-127. 
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Figure 6. Thiopstrepton effect on EF-G GTPase activity. EF-G GTPase activity on the wild type 
ribosomes is inhibited by thiostrepton already at 1 µM. On the other hand mutant ribosomes show 
considerably lower sensitivity to the antibiotic. The reaction mixture contained 0.5 µM 70S ribosomes 
(wild type, ΔL11 and A1067U), 0.1 µM EF-G, 300 µM 3H-GTP, 0.1 % Pluronic F-127, Polymix and 
variable concentrations of thiostrepton. 
Our results are consistent with previously shown data [72, 85]: A1067U and ΔL11 ribosomes 
are resistant to thiostrepton inhibition of EF-G GTPase, while EF-G GTPase activity in the 
presence of wild type ribosomes is completely inhibited at already 1 µM thiostrepton. 
1.2 Inhibition of RelA 
After establishing the EF-G GTPase system as a control, we proceeded to investigation of 
thiostrepton-mediated inhibition of RelA. Again, just like in the case of EF-G, we first 
demonstrated that in the case of RelA addition of 0.1% Pluronic F-127 does not affect the 
system (Figure 7). 
Next we performed a thiostrepton titration in stringent response system with wild type and 
ΔL11 ribosomes in the presence and absence of Pluronic F-127 (Figure 8). In the case of 
ΔL11 ribosomes the turnover rates where considerably lower then in the case of wild type 
ribosomes, consistent with L11 being crucial for RelA-activation [65, 66, 87, 88]. However, 
since inhibition curves are normalized on RelA activity in the absence of the antibiotic, this 
decrease in activity is not apparent on the figures. 
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Figure 7. Pluronic F-127 does not affect the activity of RelA. The reaction mixture contained 100 
nM RelA, 0.5 µM 70S, 0.3 mM 3H-labeled GDP, 1 mM ATP, 0.1 % Pluronic F-127, Polymix.  
Surprisingly, in the presence of Pluronic F-127 we observed no inhibition of RelA in the 
presence of as much as 10 µM of thiostrepton (Figure 8A). In the absence of Pluronic F-127 
we observed ΔL11-insensitive inhibition at concentrations at least ten times higher than these 
required for the inhibition of EF-G GTPase in the presence of thiostrepton-sensitive 
ribosomes (Figure 6). The extent of RelA inhibition was consistent with that reported in the 
literature [67, 81]. 
  
Figure 8. Nonspecific effect of thiostrepton on RelA activity in the presence (left) and absence of 
Pluronic F-127 (right). In the presence of Pluronic F-127 there is virtually no inhibitory effect of 
thiostrepton on EF-G GTPase activity, both in the case of wild type ribosomes and ΔL11 ribosomes. 
In the absence of Pluronic F-127 thiostrepton nonspecifically inhibits RelA activity at high 
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concentrations, independently of L11 protein. The reaction mixture contained 100 nM RelA, 0.5 µM 
70S, 0.3 mM 3H-labeled GDP, 1 mM ATP, Polymix and variable concentrations of thiostrepton.  
 
2. Effects of ppGpp analogues 
2.1 Inhibition of EF-G GTPase 
As a specificity control for RelA inhibition we used one of the ppGpp targets - GTPase EF-G 
(Figure 9). Titration with Relacin [78] demonstrated no significant effects on GTPase activity 
of EF-G, indicating good specificity of the compound towards inhibition of the stringent 
response. 
 
Figure 9. Relacin does not significantly affect EF-G GTPase activity. The reaction mixture 
contained 0.5 µM 70S ribosomes, 0.1 µM EF-G, 300 µM 3H-GTP, Polymix and variable 
concentrations of Relacin. 
2.2 Inhibition of RelA 
Recently our laboratory has shown that ppGpp regulates its own production by directly 
activating RelA [88], which is  seemingly contradictory to RelA inhibition by ppGpp-based 
compounds [76-78]. We carried out a reaction in a stringent response system increasing 
 30 
ppGpp concentration up to 1 mM (Figure 8), resolving the contradiction: ppGpp activates 
RelA at low concentrations (up to 200 µM) and inhibits it at higher concentrations. 
  
Figure 10. ppGpp is activating RelA protein at low concentrations and inhibiting it at higher 
concentrations. The reaction mixture contained 100 nM RelA, 0.5 µM 70S, 0.3 mM 3H-labeled GDP, 
1 mM ATP, Polymix and variable concentrations of ppGpp. 
Next, we proceeded to characterization of Relacin (Figure 11), a ppGpp analogue  has been 
shown to specifically inhibit RelA activity and reduce ppGpp production both in vitro and in 
vivo [78]. Results from our in vitro stringent response system experiment are consistent with 
the previously showed data (Figure 12): Relacin does inhibit RelA in vitro, and the efficiency 
of inhibition is low – lower than that of the parental compound, ppGpp. The probable cause of 
this is substitution of highly charged phosphate groups with less charged residues. Note that 
all the following experiments (with exception of that presented on Figure 15) are performed 
in the presence of 100 µM ppGpp resulting in activation of the in vitro stringent response 
system. 
Since Relacin is effective in bacterial cells only at very high concentrations [78], consistent 
with its low efficiency in vitro (Figure 12), we have proceeded to testing several other ppGpp 
derivatives in the search for a more efficient stringent response inhibitor. Namely, we 
investigated the effect of ppApp and 6-thio-ppGpp (Figure 13). 6-thio-ppGpp is a UV-
dependent crosslinkable derivate of ppGpp recently used to map the ppGpp binding site on E. 
coli RNAP [89], and a similar approach could potentially be employed to investigate the 
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structural basis for the ppGpp-mediated activation of RelA. In comparison with the parental 
molecule – ppGpp - these molecules have modifications in the nucleotide base. 
 
 
Figure 11. Chemical structure of Relacin. In comparison to ppGpp, in Relacin phosphate groups are 
substituted with less charged peptide-like moieties, and guanine base is carrying a iBu protection 
group. 
 
Figure 12. Inhibitory effect of Relacin on RelA activity. The reaction mixture contained 100 nM 
RelA, 0.5 µM 70S, 0.3 mM 3H-labeled GDP, 1 mM ATP, Polymix and variable concentrations of 
Relacin. 
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Figure 13. Chemical structures of ppApp (left) and thio-ppGpp (right). In comparison to the 
parental ppGpp, ppApp molecule has Adenine nucleobase instead of Guanine and thio-ppGpp has a 
sulfur atom at the sixth position of Guanine base. 
Surprisingly, both of these compounds turned out to be more efficient stringent response 
inhibitors than both Relacin and ppGpp, significantly inhibiting RelA already at a 
concentration of 100 µM (Figure 14). 
We have also tested ppApp-mediated activation of RelA (Figure 15). Unlike ppGpp (Figure 
10), even at low concentrations ppApp did not activate the in vitro stringent response system, 
suggesting that the identity of the nucleotide base is essential. 
 
  
Figure 14. ppApp and thio-ppGpp efficiently inhibit RelA at already 100 µM concentration. The 
reaction mixture contained 100 nM RelA, 0.5 µM 70S, 0.3 mM 3H-labeled GDP, 1 mM ATP, 
Polymix and variable concentrations of ppApp (left) or 6-thio-ppGpp (right). 
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Figure 15. Unlike ppGpp, ppApp does not activate stringent response, even at low 
concentrations. The reaction mixture contained 100 nM RelA, 0.5 µM 70S, 0.3 mM 3H-labeled GDP, 
1 mM ATP, Polymix and variable concentrations of ppApp. 
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Discussion and outlook 
Inhibition of the stringent response has been recently recognized as promising target for 
developing novel antibacterials [90], since this global regulatory mechanism is implicated in 
bacterial virulence, antibiotic tolerance and biofilm formation [24, 25, 28]. In this thesis I 
have investigated two potential stringent response inhibitors: antibiotic thiostrepton and three 
ppGpp analogues: Relacin, 6-thio-ppGpp and ppApp.    
Inhibition of RelA by thiostrepton is seemingly a well-documented phenomenon: it was 
demonstrated in vitro in numerous publications [67, 81, 91, 92], starting with a pioneering 
work by Haseltine and colleagues [93]. However, all of the reports used only one – and 
relatively high – concentration of the antibiotic and never tested selectivity of the effects 
using thiostrepton-resistant ribosomes. Therefore we have investigated this phenomenon in 
more detail. 
Since thiostrepton has a tendency for precipitation, we have used a nonionic surfactant 
Pluronic F-127 to stabilize the solution. Surprisingly, in the presence of Pluronic F-127 we 
observed no inhibition of RelA by thiostrepton (Figure 8A), while control experiments with 
EF-G GTPase demonstrated efficient and specific inhibition (Figure 6). In the absence of 
Pluronic F-127 we have recreated RelA inhibition reported in the literature (Figure 8B), 
however it required considerably higher concentrations of the antibiotic as compared to 
inhibition of EF-G and was insensitive to ribosomal mutations leading to thiostrepton 
resistance. We concluded that inhibition of the stringent response by thiostrepton is, most 
likely, an artifact caused by the precipitation of thiostrepton and is, therefore, unlikely to serve 
as a route for developing specific stringent response inhibitors. 
Our second direction – investigations of ppGpp analogues – demonstrated that these 
compounds are more likely to lead to the development of a specific stringent response 
inhibitor. First we characterized Relacin [78] and showed that this compound has very little 
effect on EF-G GTPase (Figure 9), and inhibits RelA with efficiency similar to that of the 
parental compound, ppGpp (compare Figure 10 and Figure 12). However, even though 
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seemingly specific, Relacin is not very efficient requiring concentrations of about 1 mM for 
significant inhibition of RelA in vitro. 
Next, we examined two ppGpp analogues – ppApp and 6-thio-ppGpp – which turned out to 
be considerably more efficient inhibitors of stringent response than ppGpp and Relacin, 
inhibiting RelA already at 100 µM concentration. Unlike Relacin, which in comparison with 
ppGpp has alterations in phosphate moieties, ppApp and 6-thio-ppGpp have modifications at 
the nucleotide base, suggesting that modification of nucleobase is a promising way to 
development of a specific and potent stringent response inhibitor.  
Our future plans for development of ppGpp analogues as promising antimicrobial drugs are as 
follows: 
1) To set up an in vitro transcription system for testing the effects of ppGpp based 
compounds on the RNAP – the main ppGpp target, and the most likely candidate for 
the off-target effects. Since ppApp has been shown to have no effect on the RNAP 
from Thermus thermophilus [67], ppApp-based inhibitors are likely to be more 
specific than ppGpp-based. 
2) To synthesize and test a new generation of ppGpp analogues containing modifications 
of both phosphates and nucleobase thus improving pharmacokinetics and specificity of 
the compounds respectively. The two compounds planned for the next step are 6-thio-
Relacin and A-Relacin (Figure 16). 6-thio-Relacin has a sulfur atom at the sixth 
position of Guanine base and does not have iBu protection group of the parental 
compound. A-Relacin has a Guanine base replaced by Adenine.  
 
Figure 16. Chemical structures of Thio-Relacin (left) and A-Relacin (right). 
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3) To investigate the crosstalk between ppGpp-based RelA inhibitors and ppGpp. 
Specifically, we would like to determine if ppGpp potentiates or protects from the 
effects of the inhibitory effects of the ppGpp analogues. This in vitro experiment will 
indicate whether stringent cells are either more or less sensitive to the inhibitors 
compared to cells with low ppGpp levels. 
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Conclusions 
 
1) The inhibitory effect of the thiostrepton on the stringent response is most likely an artifact 
caused by precipitation of thiostrepton at high concentrations and thus interfering with the 
RelA activity nonspecifically. 
2) ppGpp-based stringent response inhibitor Relacin is a weak, but potentially specific 
inhibitor with almost nondeductible off-target effect on EF-G GTPase.  
3) Modification of the nucleotide base of the ppGpp molecule is a promising route for 
developing more potent inhibitors of the stringent response: ppApp and 6-thio-ppGpp have 
potency at least ten times higher then that of Relacin and ppGpp. 
4) ppApp, unlike ppGpp, does not activate RelA in vitro, suggesting that identity of the 
nucleotide base is crucial for the activation. 
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Bakteriaalse poomisvastuse inhibiitorite, tiostreptooni ja ppGpp 
analoogide, iseloomustamine 
Jelena Beljantseva 
Resümee 
Bakteriaalne poomisvastus on alarmoonimolekuli ppGpp poolt vahendatud bakteri üks 
põhilisi adaptatsioonimehhanism stressitingimustele. ppGpp avaldab oma aktiivsust 
moduleerides erinevaid rakusiseseid ensüüme, sh RNA polümeraasi, translatsioonilisi 
GTPaase, DnaG primaasi, ja nagu meie laboris hiljuti avastati, ka RelA valku, mis on 
ribosoomist sõltuv ppGpp-d produtseeriv ensüüm. Kuna poomisvastus on seotud bakterite 
virulentsusega, antibiootikumresistentsusega ja biofilmi tekkega, omab spetsiifiliste 
poomisvastuse inhibiitorite leidmine suurt kliinilist tähtsust.    
Antud töös uurisin ma kaht tüüpi potentsiaalseid poomisvastuse inhibiitoreid: antibiootikumi 
tiostreptoon ja ppGpp-analoogseid molekule. Tiostreptoon pidurdab ribosoomi võimet 
aktiveerida translatsioonilisi GTPaase. Tiostreptooni inhibeeriv mõju RelA valgule on küll 
põhjalikult kirjeldatud, kuid seda ei ole detailselt uuritud, mis loob vajaduse antud uuringu 
järele.  Praeguseks väljaarendatud ppGpp-analoogsed RelA inhibiitorid on madala 
efektiivsuse ja biosaadavusega.  
Võrreldes tiostreptooni mõju RelA valgule ja translatsioonilisele GTPaasile EF-G-le 
metsiktüüpi või tiostreptoon-resistentsete ribosoomide juuresolekul, leidsime, et tiostreptooni 
inhibeeriv mõju RelA valgule on mittespetsiifiline, tingitud antibiootikumi väljasadenemisest 
kõrgetel kontsentratsioonidel. Seega võib järeldada, et tiostreptooni modifitseerimine ei vii 
spetsiifilise poomisvastuse inhibiitori leidmiseni. Teisalt näitasime, et kaks ppGpp-analoogset 
molekuli, ppApp ja 6-tio-ppGpp, on vähemalt ühe suurusjärgu võrra efektiivsemad 
poomisvastuse inhibiitorid kui seni kirjeldatud ppGpp analoogid. Antud töö tulemused 
näitavad, et lämmastikaluste keemiline modifitseerimine on potentsiaalne strateegia 
arendamaks spetsiifilisi ja efektiivseid poomisvastuse inhibiitoreid. 
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